PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.\', \'Laboratory of Retrovirology, The Rockefeller University, New York, NY.\', \'Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.\', \'Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY.\', \'Laboratory of Animal Reproduction and Biotechnology, Colorado State University, Fort Collins, CO.\', \'Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC.\', \'Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.\', \'Howard Hughes Medical Institute, The Rockefeller University, New York, NY.\']
?:citedBy
  • -1
?:creator
?:doi
  • e2020199310.1084/jem.20201993
?:doi
?:hasPublicationType
?:journal
  • The Journal of experimental medicine
is ?:pmid of
?:pmid
?:pmid
  • 33211088
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33211088>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33211088>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all